Results 191 to 200 of about 2,901,254 (317)

Targeting the mevalonate pathway with statins overcomes acquired resistance to KRAS^G12C inhibitors in non-small cell lung cancer. [PDF]

Exp Hematol Oncol
Lin W, Chen QA, Yang Y, Gao Y, He J.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Adult-onset acquired port-wine stain in the absence of trauma: A case report. [PDF]

JAAD Case Rep
Almesfer AM, Wani ZA, Alobaid AS, Alrubaiaan MT, Alanazi WT.   +4 more
europepmc   +1 more source

ACQUIRED MYOPIA [PDF]

British Journal of Ophthalmology, 1933
openaire   +2 more sources

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

Global prevalence and determinants of hospital-acquired COVID-19: protocol for a systematic review and meta-analysis. [PDF]

BMJ Open
Ribaric NL, O'Neill-Byrne Z, Hellinger A, Pan D, Wilson NM, Viola IM, Walsh TS, Lawton T, Afanasjevs S, Calabria C, De Angelis F, Brehm TT, Zapf A.   +12 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Lineage-Specific Associations between the Resistome and Mobilome across 10,500 Globally Distributed <i>Acinetobacter baumannii</i> Genomes. [PDF]

Comput Struct Biotechnol J
Yaikhan T, Suwannasin S, Dechathai T, Singkhamanan K, Chusri S, Pomwised R, Wonglapsuwan M, Surachat K.   +7 more
europepmc   +1 more source

Acquired onychoheterotropia

BMJ Case Reports
Hazarika, Neirita, Konsam, Nirupama, Paonam, Rikita   +2 more
openaire   +2 more sources

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source